Ide-Cel's Benefit on PF Survival: Doris Hansen, MD

Video

The hematologist from Moffitt Cancer Center discussed the survival benefit of ide-cel in the phase 2 KarMMa trial.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Doris Hansen, MD, assistant member, department of blood and marrow transplant and cellular immunotherapy. Moffitt Cancer Center, about the progression-free survival (PFS) benefit yielded by idecabtagene vicleucel (ide-cel; Abecma).

The phase 2 KarMMa trial (NCT03361748) demonstrated an overall response rate of 73% in patients with pretreated relapsed/refractory multiple myeloma. Median PFS was 8.6 months in patients with R/R MM.

The study examined the safety and efficacy of ide-cel in this patient population and was pivotal because it provided a new novel therapy to those who otherwise have limited options, according to Hansen. Patients with relapsed/refractory multiple myeloma often have a median PFS of 2 to 3 months, according to Hansen. However, patients who receive a BCMA-targeted CAR T-cell therapy experience improved outcomes, Hansen continues.

For example, results from the KarMMa study showed that patients who achieved a deep response with ide-cel, or a complete remission or better, had a median PFS of approximately 22 months, and a duration of response of 21 months. These results held up with a longer follow-up, Hansen concludes.

Related Videos
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
© 2024 MJH Life Sciences

All rights reserved.